The headline quarter was mixed versus the market’s setup. Adjusted EPS of $0.42 essentially matched the published consensus of roughly $0.42–$0.43, but sales of $1.591 billion were about 4% below the published $1.66 billion expectation. Operating profit was more resilient than revenue: adjusted EBITDA reached $247 million, near the top of the company’s prior $220–$250 million Q2 range. The result is not a clean beat: pricing protected earnings, while demand/volume came in softer. (Total Chemours — Financial Highlights)
| Metric | Q2 2026 actual | Comparison | Read-through |
|---|---|---|---|
| Net sales | $1.591B | $1.615B year ago; ~$1.66B published consensus | 1% lower year over year; missed expectations |
| Adjusted EPS | $0.42 | $0.61 year ago; ~$0.42–$0.43 published consensus | Roughly in line, but down 31% year over year |
| Adjusted EBITDA | $247M | $260M year ago; prior company guide $220M–$250M | Near the high end of guidance, but still down 5% |
| Free cash flow | $114M | $50M year ago | Material improvement in quarterly cash generation |
| Net leverage | 4.4x | 4.6x comparative trailing-period ratio | Moving down, but remains elevated |
| Full-year adjusted EBITDA outlook | $775M–$825M | Unchanged | No upgrade despite a high-end Q2 EBITDA result |
Pricing, not underlying volume, did the work. Companywide price rose 2%, but volume fell 4%. TSS held its EBITDA margin at a strong 36%, yet Opteon refrigerant sales fell 10% year over year after an unusually strong 2025 channel-fill period. TT pricing improved, but its volume also declined 2% and margin stayed only 7%. This matters because the sales miss was broad demand/mix pressure rather than a one-off accounting issue. (Quarterly Change in Net Sales; Segment Financial and Operating Data)
The better cash result is real progress, but it does not remove the balance-sheet overhang. Free cash flow more than doubled year over year to $114 million, and the company used land-sale proceeds plus organic cash to repay part of its euro term loan. Net debt stood at $3.243 billion and net leverage at 4.4x. But stockholders’ equity turned to negative $49 million from positive $250 million at year-end, while environmental-remediation liabilities rose to $795 million from $618 million. (Liquidity and Capital Allocation; Consolidated Balance Sheets; Free Cash Flow Reconciliation)
The GAAP loss shows the legacy-liability burden is still substantial. The reported loss was $274 million, even after a $266 million gain on asset sales, because the adjusted-results bridge excludes $225 million of litigation-related charges and $144 million of environmental charges in the quarter. Those exclusions help isolate operating performance, but they do not make the obligations disappear; they remain central to the financial-risk picture. (Consolidated Statements of Operations; GAAP Net Loss to Adjusted EBITDA Reconciliation)
Keeping full-year guidance unchanged limits the upside message. Management retained its $775–$825 million adjusted EBITDA and 1%–5% sales-growth outlook, while guiding Q3 EBITDA down to $175–$205 million as TSS faces weaker seasonal demand and elevated Opteon channel inventories. TT pricing and a more normalized APM plant are offsets, but the filing does not raise the full-year earnings bar after the near-top-end Q2 EBITDA result. (Third Quarter 2026 Outlook; Full Year 2026 Outlook)
Read the original 8-K on SEC EDGAR ↗